Analysis shows that vidaza prolongs survival in patients with higher-risk myelodysplastic syndromes

December 11, 2008

The Myelodysplastic Syndromes (MDS) Foundation announced today that a subanalysis of the AZA-001 phase III international clinical trial shows that treatment with VIDAZA (azacitidine) can extend overall survival and reduce the risk of death in elderly higher-risk MDS patients.

Dr. John F. Seymour of the Peter MacCallum Cancer Institute in Victoria, Australia presented the analysis at the 50th Annual Meeting of the American Society of Hematology in San Francisco. The results showed that 55 percent of patients in the trial had significantly higher overall survival rates at two years when treated with VIDAZA, as compared to patients treated with conventional care regimens (CCR).

"Dr. Seymour's analysis shows the major recent clinical advancements in treatments for elderly, higher-risk MDS patient," said Kathy Heptinstall, Operating Director of the Myelodysplastic Syndromes Foundation. "We are hopeful about the potential of new therapies, like VIDAZA, which are helping MDS patients to live longer and with a better quality of life."

The analysis presented by Dr. Seymour is a follow-up to results from the AZA-001 trial, presented at the American Society of Clinical Oncology meeting in June, which showed that VIDAZA significantly extends overall survival for patients with MDS compared to conventional care regimens. Patients who received VIDAZA had higher one-year survival rates in all response categories, including partial remission, stable disease and hematologic improvement, compared to those who received CCR without necessarily achieving complete remission.

MDS Foundation

---

---

	100 Questions & Answers About Myelodysplastic Syndromes by Jason Gotlib (Author), Lenn Fechter (Author) MDS is a lethal blood disease that affects as many as 50 per 100,000 individuals over the age of 70. The disorder is five times more prevalent than AML, a form of leukemia. Whether you're a newly diagnosed patient, a survivor, or loved one of someone suffering from MDS, this book offers help. The only text available to provide both the doctor's and patient's views, 100 Questions & Answers About Myelodysplastic Syndromes, provides practical, authoritative answers to 100 of the most common questions asked. Written with commentary from actual patients, this is an invaluable resource for anyone struggling with the medical, physical, and emotional turmoil of this disease.
	Medifocus Guidebook on: Myelodysplastic Syndromes by Inc. Medifocus.com (Author), Elliot Jacob PhD. (Editor) The MediFocus Guidebook on Myelodysplastic Syndromes is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Myelodysplastic Syndromes, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Myelodysplastic Syndromes, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts,...
	Myelodysplastic Syndromes: Clinical and Biological Advances by Peter L. Greenberg (Editor) This book describes the clinical classification, underlying biological mechanisms and treatment of the myelodysplastic syndromes. Authored by international experts, the chapters cover all aspects of the myelodysplastic syndromes, from an in-depth analysis of the multifactorial nature of this disease, including an assessment of stromal, immunological and stem cell abnormalities, to a review of recent molecular and cytogenetic discoveries and insights. This book will be a valuable resource to clinicians and researchers who wish to learn more about myelodysplastic syndromes.
	The Myelodysplastic Syndromes by Judit Várkonyi (Editor) Myelodysplastic syndromes (MDS) are the most common hematological malignancies involving mostly the elderly population. The major morbidity relates to patients’ symptomatic cytopenias.MDS was previously named as  “preleukemia “ or “ smoldering leukemia” as the lack of terminal cells in MDS and because about 25% of all cases progresses into acute myeloid leukemia. According to various reports the annual incidence of MDS ranges widely from 2-12 per 100.000, increasing to 30-50 cases per 100.000 among persons aged  70  or older. It is believed that the true incidence of MDS have been underestimated however it seems to be comparable to that for multiple myeloma and chronic lymphocytic leukemia.   In the past decade much progress had been made; we know more on the disease...
	Myelodysplastic Syndromes (Hematologic Malignancies) by H. Joachim Deeg (Author), D.T. Bowen (Author), S.D. Gore (Author), Torsten Haferlach (Author), M.M. Le Beau (Author), Charlotte Niemeyer (Author) This book summarizes our current knowledge of MDS, from very basic aspects to the clinical management. It provides guidance to the diagnosis, an understanding of disease mechanisms, and a discussion of treatment strategies.
	Myelodysplastic Syndromes: Pathobiology and Clinical Management, Second Edition (Basic and Clinical Oncology) by David Steensma (Editor) Written by a team of leading authorities in pathogenesis, diagnostic techniques, and clinical management strategies in myelodysplastic syndrome (MDS), this text provides a concise, easy-to-follow review of the advances in the science, classification, diagnosis, and management of the condition. An ideal source for hematologists, oncologists, and cancer researchers, this Second Edition features: a new eight-page color insert 200 color and black-and-white illustrations reworked content organized into three sections: MDS epidemiology and biology; diagnosis, classification, and prognosis; and MDS therapy thoroughly updated chapters reflecting a shift from the topical focus as dictated by the evolution of the field New topics in Myelodysplastic Syndrome include: del(5q) and...
	The Myelodysplastic Syndromes: Pathobiology and Clinical Management (Basic and Clinical Oncology) by John Bennett (Editor) This reference provides a comprehensive overview of the latest research detailing the etiology, epidemiology, treatment, and detection of myelodysplastic syndromes (MDS)-identifying effective therapeutic regimens, adverse environmental and genetic factors, and efficient modalities of supportive care that improve patient survival and enhance quality of life. Contains recent amendments to MDS classification criteria by the World Health Organization! The Myelodysplastic Syndromes discusses · immunological abnormalities and inflammatory diseases associated with MDS · the development of therapy-related MDS · auto and allo bone marrow transplantation · the formation of apoptotic signals · pharmacologic strategies for multidrug resistance in MDS patients · the biological...
	Myelodysplastic Syndromes: Pathophysiology and Treatment : Proceedings of the Kyoto Symposium on Myelodysplastic Syndromes, Pathophysiology and ... August 1987 (International Congress Series) by Kyoto Symposium on Myelodysplastic Syndromes: Pathophysiology and Treatment (1987) (Author), Haruto Uchino (Author), Fumimaro Takaku (Author), Yataro Yoshida (Author)
	Myelodysplastic Syndromes, An Issue of Hematology/Oncology Clinics of North America, 1e (The Clinics: Internal Medicine) by Benjamin L. Ebert MD PhD (Author) Major strides have been made in the treatment and understanding of Myelodysplasia.  The United States Food and Drug Administration (FDA) has approved three new drugs for the treatment of MDS; new disease genes have been discovered; major insights have been made into the biology of the disorder; and animal models of MDS have been developed.  The articles in this issue illustrate the rapid progress in MDS research, from molecular pathophysiology to improved therapies.  Insights into the biology of MDS, the development of model systems to study MDS, and the application of new technologies with unprecedented power to interrogate the cancer genome promise to increase the rate of discovery, transforming our understanding of MDS and leading to improvements in the treatment this disease.
	Bone Marrow Failure Syndromes by Neal S. Young MD (Author) This comprehensive and clear text familiarizes readers with the most recent information concerning bone marrow failure syndromes including anemia, leukopenia, and thrombocytopenia. 12 top experts present state-of-the-art guidance on pathophysiology and treatment, with an emphasis on chemotherapy. The result is an indispensible resource on the treatment of these often life-threatening diseases.